State Street Corp Sells 113,741 Shares of Repligen Co. (NASDAQ:RGEN)

State Street Corp lowered its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 6.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,623,683 shares of the biotechnology company's stock after selling 113,741 shares during the quarter. State Street Corp owned 2.90% of Repligen worth $241,637,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of RGEN. Champlain Investment Partners LLC lifted its position in shares of Repligen by 149.0% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company's stock valued at $211,464,000 after acquiring an additional 850,345 shares during the last quarter. Thrivent Financial for Lutherans boosted its position in shares of Repligen by 240.5% in the 2nd quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company's stock valued at $75,866,000 after purchasing an additional 425,061 shares during the period. Bank of New York Mellon Corp increased its stake in Repligen by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company's stock worth $172,749,000 after purchasing an additional 237,884 shares in the last quarter. Conestoga Capital Advisors LLC raised its holdings in Repligen by 26.7% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company's stock worth $119,363,000 after buying an additional 199,322 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Repligen by 39.4% during the second quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company's stock valued at $54,149,000 after acquiring an additional 121,305 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Wolfe Research began coverage on Repligen in a research report on Thursday, November 14th. They issued a "peer perform" rating for the company. Royal Bank of Canada reiterated an "outperform" rating and set a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. Wells Fargo & Company assumed coverage on shares of Repligen in a report on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 target price on the stock. Finally, StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a research note on Friday, November 22nd. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $190.25.

Repligen Price Performance

NASDAQ:RGEN traded up $0.74 during trading hours on Thursday, reaching $155.99. The company had a trading volume of 495,600 shares, compared to its average volume of 657,348. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The stock has a 50-day moving average of $142.27 and a two-hundred day moving average of $141.78. Repligen Co. has a one year low of $113.50 and a one year high of $211.13. The firm has a market capitalization of $8.74 billion, a PE ratio of -421.59, a PEG ratio of 4.48 and a beta of 0.96.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.09. The business had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm's quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.23 EPS. Analysts forecast that Repligen Co. will post 1.52 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.